EP1095657A3 - Compositions for the regulation of cytokine activity - Google Patents

Compositions for the regulation of cytokine activity Download PDF

Info

Publication number
EP1095657A3
EP1095657A3 EP00123134A EP00123134A EP1095657A3 EP 1095657 A3 EP1095657 A3 EP 1095657A3 EP 00123134 A EP00123134 A EP 00123134A EP 00123134 A EP00123134 A EP 00123134A EP 1095657 A3 EP1095657 A3 EP 1095657A3
Authority
EP
European Patent Office
Prior art keywords
host
compositions
sulfated
acetylated
substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP00123134A
Other languages
German (de)
French (fr)
Other versions
EP1095657B1 (en
EP1095657A2 (en
Inventor
Irun R. Cohen
Ofer Lider
Liora Cahalon
Oded Shoseyov
Raanan Margalit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of EP1095657A2 publication Critical patent/EP1095657A2/en
Publication of EP1095657A3 publication Critical patent/EP1095657A3/en
Application granted granted Critical
Publication of EP1095657B1 publication Critical patent/EP1095657B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Saccharide Compounds (AREA)

Abstract

Substances comprising a N-sulfated or N-acetylated or non-sulfated N-acetylated 4-deoxy-4-en-iduronoglucosamine in substantially purified form, including compositions containing same and their uses are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of Tumor Necrosis Factor Alpha (TNF-α) can be either inhibited or augmented selectively by administration to the host of effective amounts of substances or their compositions comprising specific oligosaccharides in substantially purified form, in relation to the treatment or prevention of a medical condition which is selected from the group consisting of insulin-dependent diabetes mellitus, periodontal disease, inflammatory bowel disease, skin diseases, uveitis, rheumatic diseases, chronic inflammation, multiple sclerosis, lupus erythematosus, atherosclerosis, arthritis, vasculitis, allergy and neoplasia. The invention also relates to the initiation of a desirable immune system-related response by the host to the presence of activators, including pathogens, including viral infection, bacterial infection or fungal infection.
EP00123134A 1992-11-10 1993-11-09 Compositions for the regulation of cytokine activity Expired - Lifetime EP1095657B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97475092A 1992-11-10 1992-11-10
US974750 1992-11-10
US9673993A 1993-07-23 1993-07-23
US96739 1993-07-23
EP94901394A EP0669827B1 (en) 1992-11-10 1993-11-09 Compositions for the regulation of cytokine activity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP94901394A Division EP0669827B1 (en) 1992-11-10 1993-11-09 Compositions for the regulation of cytokine activity

Publications (3)

Publication Number Publication Date
EP1095657A2 EP1095657A2 (en) 2001-05-02
EP1095657A3 true EP1095657A3 (en) 2004-02-25
EP1095657B1 EP1095657B1 (en) 2007-01-10

Family

ID=26792027

Family Applications (2)

Application Number Title Priority Date Filing Date
EP94901394A Expired - Lifetime EP0669827B1 (en) 1992-11-10 1993-11-09 Compositions for the regulation of cytokine activity
EP00123134A Expired - Lifetime EP1095657B1 (en) 1992-11-10 1993-11-09 Compositions for the regulation of cytokine activity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP94901394A Expired - Lifetime EP0669827B1 (en) 1992-11-10 1993-11-09 Compositions for the regulation of cytokine activity

Country Status (18)

Country Link
EP (2) EP0669827B1 (en)
JP (1) JPH08506322A (en)
CN (1) CN1093904A (en)
AT (1) ATE201327T1 (en)
AU (2) AU699624B2 (en)
CA (1) CA2149116A1 (en)
DE (2) DE69334102T2 (en)
FI (1) FI952267A (en)
HR (1) HRP931389A2 (en)
HU (1) HUT70945A (en)
IL (1) IL107563A (en)
NO (1) NO951822L (en)
NZ (1) NZ258367A (en)
PL (1) PL309001A1 (en)
SI (1) SI9300586A (en)
TW (1) TW257678B (en)
WO (1) WO1994011006A1 (en)
YU (1) YU71393A (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750207B1 (en) 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
HUT70945A (en) * 1992-11-10 1995-11-28 Yeda Res & Dev Compositions for the regulation of cytokine activity contg. oligosaccharides and process to prepare them
US6846917B2 (en) 2001-01-23 2005-01-25 Massachusetts Institute Of Technology Solid- and solution-phase synthesis of heparin and other glycosaminoglycans
US7285536B2 (en) 2001-12-05 2007-10-23 Yeda Research And Development Co., Ltd. Anti-cancer therapeutic compounds
ITMI20021294A1 (en) * 2002-06-12 2003-12-12 Inalco Spa O-SULPHATED BACTERIAL POLYSACCHARIDES AND THEIR USE
US20060293275A1 (en) * 2004-03-29 2006-12-28 Toshikazu Nakamura Hgf production accelerator containing heparin-like oligosaccharide
ITMI20091445A1 (en) * 2009-08-07 2011-02-08 Inalco S P A A Socio Unico SEMI-SYNTHETIC DERIVATIVES OF K5 POLISACCARIDE FOR THE PREVENTION AND TREATMENT OF TISSUE DAMAGE ASSOCIATED WITH ISCHEMIA AND / OR REPERFUSION
PL2747565T3 (en) 2011-09-08 2017-09-29 Novozymes Bioag A/S Seed treatment methods
AU2012308443B2 (en) 2011-09-14 2017-05-04 Novozymes Bioag A/S Use of lipochito-oligosaccharides and/or chito oligosaccharides in combination with phosphate-solubilizing microorganisms to enhance plant growth
MX351416B (en) 2011-09-23 2017-10-13 Novozymes Bioag As Chitooligosaccharides and methods for use in enhancing plant growth.
CN102824352B (en) * 2011-10-11 2013-09-04 泸州医学院 Application of disaccharide compound in preparing anti-tumor medicine
CN109730006B (en) * 2019-03-19 2022-10-18 西华大学 Method for increasing melanin content in animals
CN110646557A (en) * 2019-10-12 2020-01-03 北京航空航天大学 Urine metabolic marker of glioblastoma patient carrying IDH gene mutation and application thereof
WO2021179047A1 (en) 2020-03-12 2021-09-16 Cullis Hill Sydney David Treatment for coronavirus infection and associated cytokine toxicity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084999A1 (en) * 1982-01-15 1983-08-03 D.R.O.P.I.C. (Société Civile) Process for the preparation of organic oligosaccharides, corresponding to fragments of natural muco-polysaccharides, oligosaccharides obtained and their biological applications
JPH03169821A (en) * 1989-11-28 1991-07-23 Kissei Pharmaceut Co Ltd Prostaglandin i2 forming enhancer
BE1004029A6 (en) * 1990-11-22 1992-09-08 Mol Omer De Pharmaceutical compound and pharmaceutical set for the treatment of cancer
WO1992019249A1 (en) * 1991-05-02 1992-11-12 Yeda Research And Development Co. Ltd. Compositions for the prevention and/or treatment of pathological processes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4818816A (en) * 1981-04-28 1989-04-04 Choay, S.A. Process for the organic synthesis of oligosaccharides and derivatives thereof
FR2538404B1 (en) * 1982-12-28 1985-08-23 Anic Spa
IT1195497B (en) * 1983-03-08 1988-10-19 Opocrin Spa PROCEDURE FOR THE PREPARATION OF OLIGOSACCHARIDIC FRACTIONS EQUIPPED WITH PHARMACOLOGICAL PROPERTIES FOR CHEMICAL DEGRADATION OF HEPARIN
FR2597484B1 (en) * 1986-04-17 1988-12-23 Sanofi Sa GLYCOSAMINOGLYCANS OF THE HEPARIN OR HEPARANE-SULPHATE TYPE WITH ACTIVITY ON CELL DIVISION AND DIFFERENTIATION, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS.
FR2614026B1 (en) * 1987-04-16 1992-04-17 Sanofi Sa LOW MOLECULAR WEIGHT HEPARINS WITH REGULAR STRUCTURE, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
HUT70945A (en) * 1992-11-10 1995-11-28 Yeda Res & Dev Compositions for the regulation of cytokine activity contg. oligosaccharides and process to prepare them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084999A1 (en) * 1982-01-15 1983-08-03 D.R.O.P.I.C. (Société Civile) Process for the preparation of organic oligosaccharides, corresponding to fragments of natural muco-polysaccharides, oligosaccharides obtained and their biological applications
JPH03169821A (en) * 1989-11-28 1991-07-23 Kissei Pharmaceut Co Ltd Prostaglandin i2 forming enhancer
BE1004029A6 (en) * 1990-11-22 1992-09-08 Mol Omer De Pharmaceutical compound and pharmaceutical set for the treatment of cancer
WO1992019249A1 (en) * 1991-05-02 1992-11-12 Yeda Research And Development Co. Ltd. Compositions for the prevention and/or treatment of pathological processes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199135, Derwent World Patents Index; Class B04, AN 1991-257972, XP002265425 *
LINHARDT, ROBERT J. ET. AL.: "Oligosaccharide mapping of low-molecular-weight heparins: structure and activity differences", JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, 1906 - 1990, pages 1639 - 1645, XP002265424 *
NADER, HELENA B. ET AL: "Structural requirements of heparin disaccharides responsible for hemorrhage: reversion of the antihemostatic effect by ATP", FASEB JOURNAL ( 1989 ), 3(12), 2420-4, XP001160861 *
OKAYAMA, MINORU ET AL: "Purification and characterization of novel heparan sulfate proteoglycans produced by murine erythroleukemia cells in the growing phase", JOURNAL OF BIOLOGICAL CHEMISTRY ( 1991 ), 266(6), 3808-19, XP001174105 *
RICE K G ET AL: "STUDY OF STRUCTURALLY DEFINED OLIGOSACCHARIDE SUBSTRATES OF HEPARIN AND HEPARAN MONOSULFATE LYASES", CARBOHYDRATE RESEARCH, ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, NL, vol. 190, no. 2, 1 July 1989 (1989-07-01), pages 219 - 233, XP000026506, ISSN: 0008-6215 *
Y. KARIYA ET AL.: "Preparation of unsaturated disaccharides by eliminative cleavage of heparin and heparan sulfate with heparitinases.", COMP. BIOCHEM. PHYSIOL., vol. 103B, no. 2, 1992, pages 473 - 479, XP000561260 *
YAMADA S ET AL: "ONE- AND TWO-DIMENSIONAL H-NMR CHARACTERIZATION OF TWO SERIES OF SULFATED DISACCHARIDES PREPARED FROM CHONDROITIN SULFATE AND HEPARAN SULFATE/HEPARIN BY BACTERIAL ELIMINASE DIGESTION", JOURNAL OF BIOCHEMISTRY, JAPANESE BIOCHEMICAL SOCIETY, TOKYO, JP, vol. 112, no. 4, 1992, pages 440 - 447, XP001160880, ISSN: 0021-924X *

Also Published As

Publication number Publication date
HU9501373D0 (en) 1995-06-28
SI9300586A (en) 1994-09-30
ATE201327T1 (en) 2001-06-15
CA2149116A1 (en) 1994-05-26
NO951822L (en) 1995-06-29
EP0669827A4 (en) 1996-08-28
HUT70945A (en) 1995-11-28
NZ258367A (en) 1997-02-24
AU6478398A (en) 1998-06-25
EP0669827A1 (en) 1995-09-06
HRP931389A2 (en) 1995-04-30
AU686581B2 (en) 1998-02-12
DE69330252T2 (en) 2002-02-07
EP1095657B1 (en) 2007-01-10
PL309001A1 (en) 1995-09-18
JPH08506322A (en) 1996-07-09
AU699624B2 (en) 1998-12-10
YU71393A (en) 1997-05-28
DE69334102D1 (en) 2007-02-22
NO951822D0 (en) 1995-05-09
WO1994011006A1 (en) 1994-05-26
AU5599394A (en) 1994-06-08
FI952267A (en) 1995-07-10
TW257678B (en) 1995-09-21
IL107563A (en) 2006-12-31
IL107563A0 (en) 1994-02-27
DE69330252D1 (en) 2001-06-28
EP1095657A2 (en) 2001-05-02
CN1093904A (en) 1994-10-26
EP0669827B1 (en) 2001-05-23
FI952267A0 (en) 1995-05-10
DE69334102T2 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
EP1095657A3 (en) Compositions for the regulation of cytokine activity
CA2118121C (en) Methods and compositions for the treatment of diseases with interferon while reducing side effects
NZ251320A (en) Bis-aromatic alpha,beta-unsaturated ketones, preparation and use in pharmaceutical compositions
CA2170047A1 (en) Androstenone derivative
DE69324671D1 (en) IMPROVED ALPHA INTERFERON COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF FROM LEUKOCYTES OF THE HUMAN PERIPHERAL BLOOD
EP0765160A4 (en)
IL107518A0 (en) Therapeutic and diagnostic compositions comprising purified surface modifiers to prevent particle aggregation during sterilization
EP0876143A4 (en) Tumor necrosis factor alpha (tnf-alpha) inhibiting pharmaceuticals
CA2067381A1 (en) Treatment of hiv infections and compounds useful therein
AU4245289A (en) Psyllium-containing products
WO1997028812A3 (en) Pharmaceutical compositions for biological treatment of infections by enterococcus faecium strains resistant to antibiotics and to vancomycin in particular (vre)
CA2037779A1 (en) Antibiotic ge 2270 factors b1, b2, c1, c2, d1, d2, e and t
AU7681091A (en) Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases
CA2075926A1 (en) Hydroquinone amino-acid esters, method of preparation, and pharmaceutical or cosmetic compositions containing them
CA2078805A1 (en) Cytokine Preparation
AU6942896A (en) Use of muteins of wild-type cytokines as immunogens
Zicari et al. Stimulation of macrophages with IFNγ or TNFα shuts off the suppressive effect played by PGE2
RU93054957A (en) METHOD FOR PRODUCING VEGETABLE BIOLOGICALLY ACTIVE POLYSACCHARIDE
WO1998036758A3 (en) Therapeutic agents containing oxygen anion radicals and the use thereof in the treatment of parkinson's disease
Gemmell Interaction of Clostridium difficile toxin with human polymorphonuclear leukocyte function.
Roekke et al. Endotoxin and cytokines in plasma and clinical manifestations during treatment of septicaemia with imipenem or cefuroxime/metronidazole
WO1994008474A3 (en) Medical food and method of administration
RU95113594A (en) Composition for cytokin activity regulation
GR1002969B (en) Medicinal preparation based on fetal cell suspension, having immune substituting effect and method of treatment of acquired immune deficiency syndrome (HIV infection) with the use of said preparation.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 669827

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07H 11/00 B

Ipc: 7A 61K 31/70 A

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 20040825

AKX Designation fees paid

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20050509

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 0669827

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070110

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070110

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070110

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69334102

Country of ref document: DE

Date of ref document: 20070222

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070611

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: YEDA RESEARCH AND DEVELOPMEMT CO., LTD.

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20071011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070110

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20071127

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20081107

Year of fee payment: 16

Ref country code: CH

Payment date: 20081117

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20081112

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20081105

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081109

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071109

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20071113

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081110

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20091109

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20100730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091130

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091109